Massachusetts S689 mandates coverage for biomarker testing in health insurance plans.
Massachusetts S689 requires health insurance plans to cover biomarker testing, which analyzes tissue, blood, or other biospecimens for biomarkers. This testing is essential for diagnosing, treating, managing, or monitoring diseases. Coverage must be provided without causing care disruptions, such as multiple biopsies. If prior authorization is needed, insurers must respond within 24 hours if a delay risks the patient's health. Patients and practitioners can easily request exceptions to coverage policies or adverse review determinations.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.